You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2002–07
Notes:
1. The trends represent the available information on national street-level prices (either typical or mean prices, depending on countries and data available) for each drug in the EU Member States and Norway, weighted by country population sizes to form an overall EU trend. Prices have been adjusted for national inflation rates (base year 2002) and all series indexed to a base of 100 in 2002.
2. Countries missing drug price information for two or more consecutive years are not included in the trend calculations: the trend for LSD is based on seven countries (64 % of the EU population 15-64), heroin brown on eight countries (51 % of the EU population 15-64), amphetamine on ten countries (62 % of the EU population 15-64), cocaine on 12 countries (66 % of the EU population 15-64), ecstasy on 13 countries (70 % of the EU population15-64), herbal cannabis on 13 countries (73 % of the EU population 15-64), and cannabis resin on 14 countries (74 % of the EU population15-64).
3. Additionally, where 2007 data are missing (eleven cases) 2006 prices are used; for missing 2002 data (eleven cases) 2003 prices are used; data missing for other years (eighteen cases) have been interpolated from adjacent years.
Sources:
Price data: Reitox national focal points
(see the help page for information about formats etc.)